GlaxoSmithKline PLC and its development partner Innoviva Inc. have released top-line results from a second group of patients – those with asthma – to take part in the “real-world” Salford Lung Study. The results show that once-daily inhaled Relvar Ellipta (fluticasone furoate plus vilanterol; known as Breo Ellipta in the US) was associated with significantly more patients achieving an improvement in their asthma control than those treated with “usual care.”
The study design is claimed to be revolutionary, but those wanting more extensive data from the asthma study will have...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?